University of Virginia, Charlottesville, VA 22908-0736, USA.
Circ Res. 2011 Oct 14;109(9):993-1002. doi: 10.1161/CIRCRESAHA.111.248898. Epub 2011 Sep 1.
In normal and diseased vascular smooth muscle (SM), the RhoA pathway, which is activated by multiple agonists through G protein-coupled receptors (GPCRs), plays a central role in regulating basal tone and peripheral resistance. This occurs through inhibition of myosin light chain phosphatase, leading to increased phosphorylation of the myosin regulatory light chain. Although it is thought that specific agonists and GPCRs may couple to distinct RhoA guanine nucleotide exchange factors (GEFs), thus raising the possibility of selective targeting of specific GEFs for therapeutic use, this notion is largely unexplored for SM contraction.
We examine whether p63RhoGEF, known to couple specifically to Gα(q/11) in vitro, is functional in blood vessels as a mediator of RhoA activation and if it is selectively activated by Gα(q/11) coupled agonists.
We find that p63RhoGEF is present across SM tissues and demonstrate that silencing of the endogenous p63RhoGEF in mouse portal vein inhibits contractile force induced by endothelin-1 to a greater extent than the predominantly Gα(12/13)-mediated thromboxane analog U46619. This is because endothelin-1 acts on Gα(q/11) as well as Gα(12/13). Introduction of the exogenous isolated pleckstrin-homology (PH) domain of p63RhoGEF (residues 331-580) into permeabilized rabbit portal vein inhibited Ca2+ sensitized force and activation of RhoA, when phenylephrine was used as an agonist. This reinforces the results based on endothelin-1, because phenylephrine is thought to act exclusively through Gα(q/11).
We demonstrate that p63RhoGEF selectively couples Gα(q/11) but not Gα(12/13), to RhoA activation in blood vessels and cultured cells and thus mediates the physiologically important Ca2+ sensitization of force induced with Gα(q/11)-coupled agonists. Our results suggest that signaling through p63RhoGEF provides a novel mechanism for selective regulation of blood pressure.
在正常和病变的血管平滑肌(SM)中,RhoA 通路通过 G 蛋白偶联受体(GPCR)被多种激动剂激活,在调节基础张力和外周阻力方面发挥着核心作用。这是通过肌球蛋白轻链磷酸酶的抑制作用实现的,导致肌球蛋白调节轻链的磷酸化增加。虽然人们认为特定的激动剂和 GPCR 可能与不同的 RhoA 鸟嘌呤核苷酸交换因子(GEF)偶联,从而为治疗用途选择性靶向特定的 GEF 提供了可能性,但这一概念在 SM 收缩方面在很大程度上尚未得到探索。
我们研究了 p63RhoGEF 是否在血管中作为 RhoA 激活的介质起作用,并且是否可以被 Gα(q/11)偶联的激动剂选择性激活,因为它已知在体外特异性偶联至 Gα(q/11)。
我们发现 p63RhoGEF 存在于 SM 组织中,并证明在小鼠门静脉中沉默内源性 p63RhoGEF 可抑制内皮素-1诱导的收缩力,其程度大于主要由 Gα(12/13)介导的血栓烷类似物 U46619。这是因为内皮素-1作用于 Gα(q/11)和 Gα(12/13)。将 p63RhoGEF 的外源性分离的 pleckstrin-homology(PH)结构域(残基 331-580)引入透化的兔门静脉中,当使用苯肾上腺素作为激动剂时,抑制 Ca2+敏化力和 RhoA 的激活。这加强了基于内皮素-1 的结果,因为苯肾上腺素被认为仅通过 Gα(q/11)起作用。
我们证明 p63RhoGEF 选择性地将 Gα(q/11)而不是 Gα(12/13)偶联到血管和培养细胞中的 RhoA 激活,从而介导与 Gα(q/11)偶联的激动剂诱导的生理重要的 Ca2+敏化力。我们的结果表明,通过 p63RhoGEF 的信号传递为选择性调节血压提供了一种新的机制。